Urgent.News

What's breaking now, across thousands of outlets.

Science

First evidence from a Chinese population supports review of long-term blood monitoring for local clozapine use

An international research team led by the Department of Psychiatry, School of Clinical Medicine, LKS Faculty of Medicine of the University of Hong Kong (HKUMed), has completed a long-term population-based research study to improve care for people with treatment-resistant schizophrenia (TRS), the most severe form of this mental health condition. The findings reinforce the importance of timely…

First evidence from a Chinese population supports review of long-term blood monitoring for local clozapine use

A recent 20-year study led by the University of Hong Kong's Department of Psychiatry has found crucial evidence supporting a review of Hong Kong's long-term blood monitoring requirements for clozapine use. Clozapine, a key antipsychotic medication for treatment-resistant schizophrenia (TRS), requires regular blood tests to monitor for potentially life-threatening neutropenia. Current guidelines mandate monthly testing while patients are on clozapine, which can be burdensome for patients and healthcare services.

The research, published in The British Journal of Psychiatry, examined data from 4,868 patients who started clozapine and compared it to 38,277 patients receiving other second-generation antipsychotics. The study revealed that the risk of clozapine-induced neutropenia was highest during the first 18 weeks of treatment but significantly decreased after approximately two years. After this period, the risk profile for clozapine users was similar to that of patients on other antipsychotics.

Professor Sherry Chan, the study's corresponding author, emphasized that clozapine can be life-changing for those with TRS, but the current monthly blood tests can discourage patients from starting or continuing treatment. The findings provide evidence for a more personalized monitoring approach, suggesting weekly monitoring during the first 18 weeks, followed by monthly tests for up to two years. Beyond this point, monitoring could align with the frequency of non-clozapine second-generation antipsychotics.

The study also noted that risk patterns varied by age and sex, suggesting that a more individualized monitoring strategy may be beneficial. Professor Chan stressed that patients should always consult their healthcare providers before making any changes to their medication or testing schedule.

These findings complement two other large-scale studies from Hong Kong. An 18-year study found that continuous clozapine use reduced the risk of suicide and all-cause mortality compared to other antipsychotics. A 20-year study showed that periods of clozapine treatment were associated with a 79% lower risk of psychiatric hospitalization compared to other antipsychotics.

While these observational studies cannot definitively prove that clozapine directly causes these outcomes, the large datasets, long follow-up periods, and complementary designs provide valuable real-world evidence for patients and clinicians in Hong Kong. The researchers hope these findings will help reduce barriers to treatment, support informed decision-making between patients and healthcare professionals, and ultimately improve the quality of care for patients with TRS.

Written by urgent.news from Medical Xpress's reporting — not their text. Machine-written — may contain errors; check the original before relying on it.

Read the original at medicalxpress.com →

More in Science

More from Tuesday 17 November →